Home / 2019 / March / 26

Daily Archives: March 26, 2019

Wildflower Brands Inc. (CSE: SUN) (OTCQB: WLDFF) Featured in NetworkNewsWire Publication on Soaring Hemp-Based CBD Industry

NEW YORK, March 26, 2019 (GLOBE NEWSWIRE) — via NetworkWire — NetworkNewsWire (“NNW”), a multifaceted financial news and publishing company, today announces the publication of an editorial featuring Wildflower Brands Inc. (CSE: SUN) (OTCQB: WLDFF).

To read the full editorial discussing  CBD industry forecasts following the passage of the Farm Bill, visit: http://nnw.fm/Q5q5a

Hemp is making a comeback thanks to the growing popularity of cannabidiol (CBD), an active ingredient found in many forms of cannabis. It’s an ingredient that companies such as Wildflower Brands Inc. (CSE: SUN) (OTCQB: WLDFF), a creator of plant-based health and wellness products, have been making extensive use of in recent years.

The Farm Bill has been driven in large part by the growing demand for CBD. An obscure and seldom discussed chemical a decade ago, CBD has emerged as an important consumer product. … Identified as a chemical with great potential for health and wellness, CBD has started to be marketed in its own right and is used in products such as the Wildflower Wellness line.

About Wildflower Brands

Wildflower Brands is a company headquartered in Vancouver building reputable brands and quality products that incorporate the synergistic effects of plants and their extracts. For more information, visit the company’s website at www.WildflowerBrands.co

About NetworkNewsWire

NetworkNewsWire (NNW) is a financial news and content distribution company that provides (1) access to a network of wire services via NetworkWire to reach all target markets, industries and demographics in the most effective manner possible, (2) article and editorial syndication to 5,000+ news outlets, (3) enhanced press release services to ensure maximum impact, (4) social media distribution via the Investor Brand Network (IBN) to nearly 2 million followers, (5) a full array of corporate communications solutions, and (6) a total news coverage solution with NNW Prime. As a multifaceted organization with an extensive team of contributing journalists and writers, NNW is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. By cutting through the overload of information in today’s market, NNW brings its clients unparalleled visibility, recognition and brand awareness. NNW is where news, content and information converge. For more information, please visit https://www.NetworkNewsWire.com.

Please see full terms of use and disclaimers on the NetworkNewsWire website applicable to all content provided by NNW, wherever published or re-published: http://NNW.fm/Disclaimer.

Receive Instant SMS Alerts from NetworkNewsWire

Text “STOCKS” to 77948

Forward-Looking Statements

This release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended and Section 21E of the Securities Exchange Act of 1934, as amended. All forward-looking statements are inherently uncertain as they are based on current expectations and assumptions concerning future events or future performance of the company. Readers are cautioned not to place undue reliance on these forward-looking statements, which are only predictions and speak only as of the date hereof. In evaluating such statements, prospective investors should review carefully various risks and uncertainties identified in this release and matters set in the company’s SEC filings. These risks and uncertainties could cause the company’s actual results to differ materially from those indicated in the forward-looking statements.

Corporate Communications:

NetworkWire (NW)
New York, New York
www.NetworkNewsWire.com
212.418.1217 Office
Editor@NetworkWire.com

Wildflower Brands Inc. (CSE: SUN) (OTCQB: WLDFF) Featured in NetworkNewsWire Publication on Soaring Hemp-Based CBD Industry

NEW YORK, March 26, 2019 (GLOBE NEWSWIRE) — via NetworkWire — NetworkNewsWire (“NNW”), a multifaceted financial news and publishing company, today announces the publication of an editorial featuring Wildflower Brands Inc. (CSE: SUN) (OTCQB: WLDFF).

To read the full editorial discussing  CBD industry forecasts following the passage of the Farm Bill, visit: http://nnw.fm/Q5q5a

Hemp is making a comeback thanks to the growing popularity of cannabidiol (CBD), an active ingredient found in many forms of cannabis. It’s an ingredient that companies such as Wildflower Brands Inc. (CSE: SUN) (OTCQB: WLDFF), a creator of plant-based health and wellness products, have been making extensive use of in recent years.

The Farm Bill has been driven in large part by the growing demand for CBD. An obscure and seldom discussed chemical a decade ago, CBD has emerged as an important consumer product. … Identified as a chemical with great potential for health and wellness, CBD has started to be marketed in its own right and is used in products such as the Wildflower Wellness line.

About Wildflower Brands

Wildflower Brands is a company headquartered in Vancouver building reputable brands and quality products that incorporate the synergistic effects of plants and their extracts. For more information, visit the company’s website at www.WildflowerBrands.co

About NetworkNewsWire

NetworkNewsWire (NNW) is a financial news and content distribution company that provides (1) access to a network of wire services via NetworkWire to reach all target markets, industries and demographics in the most effective manner possible, (2) article and editorial syndication to 5,000+ news outlets, (3) enhanced press release services to ensure maximum impact, (4) social media distribution via the Investor Brand Network (IBN) to nearly 2 million followers, (5) a full array of corporate communications solutions, and (6) a total news coverage solution with NNW Prime. As a multifaceted organization with an extensive team of contributing journalists and writers, NNW is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. By cutting through the overload of information in today’s market, NNW brings its clients unparalleled visibility, recognition and brand awareness. NNW is where news, content and information converge. For more information, please visit https://www.NetworkNewsWire.com.

Please see full terms of use and disclaimers on the NetworkNewsWire website applicable to all content provided by NNW, wherever published or re-published: http://NNW.fm/Disclaimer.

Receive Instant SMS Alerts from NetworkNewsWire

Text “STOCKS” to 77948

Forward-Looking Statements

This release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended and Section 21E of the Securities Exchange Act of 1934, as amended. All forward-looking statements are inherently uncertain as they are based on current expectations and assumptions concerning future events or future performance of the company. Readers are cautioned not to place undue reliance on these forward-looking statements, which are only predictions and speak only as of the date hereof. In evaluating such statements, prospective investors should review carefully various risks and uncertainties identified in this release and matters set in the company’s SEC filings. These risks and uncertainties could cause the company’s actual results to differ materially from those indicated in the forward-looking statements.

Corporate Communications:

NetworkWire (NW)
New York, New York
www.NetworkNewsWire.com
212.418.1217 Office
Editor@NetworkWire.com

Bhang Corporation’s Scott Van Rixel and Jamie Pearson Named to High Times’ Most Influential People in Cannabis

LOS ANGELES, March 26, 2019 (GLOBE NEWSWIRE) — Bhang Corporation (“Bhang” or the “Company”), the global cannabis house of brands with an extensive, award-winning portfolio of products, is proud to announce that Bhang CEO Scott Van Rixel and COO Jamie Pearson have each been recognized by High Times Magazine for their work in the cannabis industry.

Scott Van Rixel has been named to the 2018 High Times’ List of 100 Most Influential People in the Cannabis Industry and Jamie Pearson has been named one of the 2018 High Times Women of Weed, Most Influential Women in Cannabis List.

“We are honored to receive these accolades from High Times” said Scott Van Rixel, CEO of Bhang. “When I started Bhang 9 years ago, I did it with the goal of creating quality and consistent products that consumers love. Today, we are one of the most recognized cannabis brand houses on the planet and I thank all our employees who work tirelessly each day to make this possible.”

“I am proud to lead a passionate, executive team at Bhang that is 90% female” added Jamie Pearson. “Being influential is about listening, elevating others and being willing to take risks for the greater good. Bhang continues to be recognized because we lead by doing what is right before it’s required. It is our company culture.”

Bhang’s long-standing brand, history of operational execution, and innovative product portfolio were built on a strong foundation of quality and consumer safety. With a portfolio of brands comprising over 100 cannabis and CBD based products, Bhang is well positioned to capitalize on the growing consumer appetite for cannabis-derived products.

The High Times 100 celebrates the efforts of the men and women currently shaping the marijuana landscape. The High Times Women of Weed list strives to highlight the women who help shape the evolving cannabis space into an innovative, progressive, and inclusive industry.

Along with their fellow nominees, Scott will be honored at the High Times 100 private gala in Los Angeles on March 27, 2019. Jamie will be honored at the High Times Women of Weed private gala in Los Angeles on March 29, 2019.

About Bhang
Bhang’s award-winning product portfolio of over 100 cannabis and CBD products includes the most-awarded line of cannabis chocolate bars on the planet, as well as a premium collection of pre-rolls, vapes, beverages, gums, mouth sprays and Bhang-branded merchandise. From public companies to platinum recording artists and organic food companies, Bhang has mastered the art of harnessing mutually beneficial partnerships to bring safe, consistent and delicious products to the world. Learn more at gotbhang.com

Contact
Jamie Pearson
COO
j.pearson@bhangcorporation.com
406.208.3488

Nanobiotix announces its clinical registration plan in Head and Neck cancers for the United States following FDA feedback

  • Moving forward with Overall Survival (OS)-based, randomized, event-driven clinical trial for the United States
  • Pre-IND feedback from US Food and Drug Administration (FDA) provides clarity to Nanobiotix on US regulatory pathway to approval
  • Clinical trial authorization process to begin in 2H2019 with FDA filing

‘‘We are happy to announce our plan for the registration pathway in Head and Neck cancers in the US. This is a key milestone for the Company and our shareholders, and we look forward to critical next steps toward US development,’’ commented Laurent Levy, Nanobiotix’s CEO.

Paris, France; Cambridge, Massachusetts (USA); March 26, 2019 – NANOBIOTIX (Euronext: NANO – ISIN: FR0011341205 – the ‘‘Company’’), a clinical-stage nanomedicine company pioneering new approaches to the treatment of cancer, today announced that the Company has clarity on its regulatory pathway in the treatment of Head and Neck cancers for first-in-class radioenhancer NBTXR3. The announcement follows pre-IND feedback from the US FDA received on March 18, 2019.

Stage III and IV Head and Neck cancers include large primary tumors which may invade underlying structures and/or spread to regional nodes. Treatment of these locally advanced forms of the disease—which makes up more than 50% of all Head and Neck cancers—requires aggressive, concerted measures that often remain a clinical challenge with an estimated 5-year survival rate of 50% with the current standard of care.

Within the Stage III and IV Head and Neck cancers patient population, the Company targets a subpopulation of patients, who have a higher risk of recurrence, or a poorer prognosis as they have an inability to receive cisplatin, the frontline chemotherapy drug for advanced Head and Neck cancers. Additionally, the localization of the tumor focuses on oropharynx, hypopharynx, and oral cavity – representing the majority of Head and Neck cancers.

Based on US FDA feedback, the Company plans to design an Overall Survival (OS)-based, randomized, event-driven Phase II/III clinical trial. 50% of patients will receive standard of care radiotherapy combined with NBTXR3 while the other 50% will receive radiotherapy in combination with cetuximab. The expected total number of patients to participate in this global clinical trial is approximately 600, and an efficacy interim analysis is planned.

Notably, the US FDA has not objected to the use of the data from the dose-escalation phase of the Company’s European Phase I clinical trial in elderly and frail patients with locally advanced Head and Neck cancers as well as the Company’s current CMC (chemical, manufacturing and control) development plan.
The Company plans to initiate its global clinical trial authorization process with US FDA in 2H2019.

About NBTXR3

NBTXR3 is a first-in-class product candidate designed to destroy tumors and metastasis when activated by radiotherapy.

NBTXR3 has a high degree of biocompatibility and requires one single administration before the whole radiotherapy treatment. Nanobiotix believes NBTXR3 has the ability to fit into current worldwide standards of radiation care.

Nanobiotix’s broad clinical program includes 7 clinical trials. In June 2018, Nanobiotix established human proof of concept for this first-in-class product candidate in its Soft Tissue Sarcoma (STS) Phase III clinical trial.

NBTXR3 is actively being studied in head and neck cancer with locally advanced squamous cell carcinoma of the oral cavity or oropharynx in elderly and frail patients who are unable to receive chemotherapy or cetuximab and have very limited therapeutic options. Promising results from these clinical studies have been observed from the ongoing Phase I/II trial regarding the local control of tumors.

Nanobiotix is also running an Immuno-Oncology development program. In the United States, Nanobiotix has received approval from the US FDA to launch a clinical study of NBTXR3 activated by radiotherapy in combination with anti-PD1 antibodies in lung, and head and neck cancer patients (head and neck squamous cell carcinoma and non-small cell lung cancer).

The other ongoing NBTXR3 trials are treating patients with liver cancers (hepatocellular carcinoma and liver metastasis), locally advanced or unresectable rectal cancer in combination with chemotherapy, head and neck cancer in combination with concurrent chemotherapy, and prostate adenocarcinoma.

The first market authorization process (CE Marking) is ongoing in Europe in the STS indication.

About NANOBIOTIX: www.nanobiotix.com

Incorporated in 2003, Nanobiotix is a leading, clinical-stage nanomedicine company pioneering new approaches to significantly change patient outcomes by bringing nanophysics to the heart of the cell.

The Nanobiotix philosophy is rooted in designing pioneering, physical-based approaches to bring highly effective and generalized solutions to address unmet medical needs and challenges.

Nanobiotix’s first-in-class, proprietary lead technology, NBTXR3, aims to expand radiotherapy benefits for millions of cancer patients. Nanobiotix’s Immuno-Oncology program has the potential to bring a new dimension to cancer immunotherapies.

Nanobiotix is listed on the regulated market of Euronext in Paris (Euronext: NANO / ISIN: FR0011341205; Bloomberg: NANO: FP). The Company’s headquarters are in Paris, France, with a U.S. affiliate in Cambridge, MA, and European affiliates in Spain and Germany.

Contacts

Nanobiotix

Communications Department
+33 (0)1 40 26 07 55
+1 (617) 852-4835
contact@nanobiotix.com

 

Investor Relations Department
+33 (0)1 79 97 29 99
+1 (646) 241-4400
investors@nanobiotix.com

Media Relations  

France – Springbok Consultants
Marina Rosoff
+33 (0)6 71 58 00 34
marina@springbok.fr

US – RooneyPartners
Marion Janic
+1 (212) 223-4017
mjanic@rooneyco.com

Disclaimer
This press release contains certain forward-looking statements concerning Nanobiotix and its business. Such forward-looking statements are based on assumptions that Nanobiotix considers to be reasonable. However, there can be no assurance that the estimates contained in such forward-looking statements will be verified, which estimates are subject to numerous risks including the risks set forth in the reference document of Nanobiotix filed with the French Financial Markets Authority (Autorité des Marchés Financiers) under number D.17-0470 on April 28, 2017 as well as in its 2017 annual financial report filed with the French Financial Markets Authority on March 29, 2018 (a copy of which is available on www.nanobiotix.com) and to the development of economic conditions, financial markets and the markets in which Nanobiotix operates. The forward-looking statements contained in this press release are also subject to risks not yet known to Nanobiotix or not currently considered material by Nanobiotix. The occurrence of all or part of such risks could cause actual results, financial conditions, performance or achievements of Nanobiotix to be materially different from such forward-looking statements. This press release and the information that it contains do not constitute an offer to sell or subscribe for, or a solicitation of an offer to purchase or subscribe for, Nanobiotix shares in any country. At the moment NBTXR3 does not bear a CE mark and is not permitted to be placed on the market or put into service until NBTXR3 has obtained a CE mark.

Attachment

Nanobiotix announces its clinical registration plan in Head and Neck cancers for the United States following FDA feedback

  • Moving forward with Overall Survival (OS)-based, randomized, event-driven clinical trial for the United States
  • Pre-IND feedback from US Food and Drug Administration (FDA) provides clarity to Nanobiotix on US regulatory pathway to approval
  • Clinical trial authorization process to begin in 2H2019 with FDA filing

‘‘We are happy to announce our plan for the registration pathway in Head and Neck cancers in the US. This is a key milestone for the Company and our shareholders, and we look forward to critical next steps toward US development,’’ commented Laurent Levy, Nanobiotix’s CEO.

Paris, France; Cambridge, Massachusetts (USA); March 26, 2019 – NANOBIOTIX (Euronext: NANO – ISIN: FR0011341205 – the ‘‘Company’’), a clinical-stage nanomedicine company pioneering new approaches to the treatment of cancer, today announced that the Company has clarity on its regulatory pathway in the treatment of Head and Neck cancers for first-in-class radioenhancer NBTXR3. The announcement follows pre-IND feedback from the US FDA received on March 18, 2019.

Stage III and IV Head and Neck cancers include large primary tumors which may invade underlying structures and/or spread to regional nodes. Treatment of these locally advanced forms of the disease—which makes up more than 50% of all Head and Neck cancers—requires aggressive, concerted measures that often remain a clinical challenge with an estimated 5-year survival rate of 50% with the current standard of care.

Within the Stage III and IV Head and Neck cancers patient population, the Company targets a subpopulation of patients, who have a higher risk of recurrence, or a poorer prognosis as they have an inability to receive cisplatin, the frontline chemotherapy drug for advanced Head and Neck cancers. Additionally, the localization of the tumor focuses on oropharynx, hypopharynx, and oral cavity – representing the majority of Head and Neck cancers.

Based on US FDA feedback, the Company plans to design an Overall Survival (OS)-based, randomized, event-driven Phase II/III clinical trial. 50% of patients will receive standard of care radiotherapy combined with NBTXR3 while the other 50% will receive radiotherapy in combination with cetuximab. The expected total number of patients to participate in this global clinical trial is approximately 600, and an efficacy interim analysis is planned.

Notably, the US FDA has not objected to the use of the data from the dose-escalation phase of the Company’s European Phase I clinical trial in elderly and frail patients with locally advanced Head and Neck cancers as well as the Company’s current CMC (chemical, manufacturing and control) development plan.
The Company plans to initiate its global clinical trial authorization process with US FDA in 2H2019.

About NBTXR3

NBTXR3 is a first-in-class product candidate designed to destroy tumors and metastasis when activated by radiotherapy.

NBTXR3 has a high degree of biocompatibility and requires one single administration before the whole radiotherapy treatment. Nanobiotix believes NBTXR3 has the ability to fit into current worldwide standards of radiation care.

Nanobiotix’s broad clinical program includes 7 clinical trials. In June 2018, Nanobiotix established human proof of concept for this first-in-class product candidate in its Soft Tissue Sarcoma (STS) Phase III clinical trial.

NBTXR3 is actively being studied in head and neck cancer with locally advanced squamous cell carcinoma of the oral cavity or oropharynx in elderly and frail patients who are unable to receive chemotherapy or cetuximab and have very limited therapeutic options. Promising results from these clinical studies have been observed from the ongoing Phase I/II trial regarding the local control of tumors.

Nanobiotix is also running an Immuno-Oncology development program. In the United States, Nanobiotix has received approval from the US FDA to launch a clinical study of NBTXR3 activated by radiotherapy in combination with anti-PD1 antibodies in lung, and head and neck cancer patients (head and neck squamous cell carcinoma and non-small cell lung cancer).

The other ongoing NBTXR3 trials are treating patients with liver cancers (hepatocellular carcinoma and liver metastasis), locally advanced or unresectable rectal cancer in combination with chemotherapy, head and neck cancer in combination with concurrent chemotherapy, and prostate adenocarcinoma.

The first market authorization process (CE Marking) is ongoing in Europe in the STS indication.

About NANOBIOTIX: www.nanobiotix.com

Incorporated in 2003, Nanobiotix is a leading, clinical-stage nanomedicine company pioneering new approaches to significantly change patient outcomes by bringing nanophysics to the heart of the cell.

The Nanobiotix philosophy is rooted in designing pioneering, physical-based approaches to bring highly effective and generalized solutions to address unmet medical needs and challenges.

Nanobiotix’s first-in-class, proprietary lead technology, NBTXR3, aims to expand radiotherapy benefits for millions of cancer patients. Nanobiotix’s Immuno-Oncology program has the potential to bring a new dimension to cancer immunotherapies.

Nanobiotix is listed on the regulated market of Euronext in Paris (Euronext: NANO / ISIN: FR0011341205; Bloomberg: NANO: FP). The Company’s headquarters are in Paris, France, with a U.S. affiliate in Cambridge, MA, and European affiliates in Spain and Germany.

Contacts

Nanobiotix

Communications Department
+33 (0)1 40 26 07 55
+1 (617) 852-4835
contact@nanobiotix.com

 

Investor Relations Department
+33 (0)1 79 97 29 99
+1 (646) 241-4400
investors@nanobiotix.com

Media Relations  

France – Springbok Consultants
Marina Rosoff
+33 (0)6 71 58 00 34
marina@springbok.fr

US – RooneyPartners
Marion Janic
+1 (212) 223-4017
mjanic@rooneyco.com

Disclaimer
This press release contains certain forward-looking statements concerning Nanobiotix and its business. Such forward-looking statements are based on assumptions that Nanobiotix considers to be reasonable. However, there can be no assurance that the estimates contained in such forward-looking statements will be verified, which estimates are subject to numerous risks including the risks set forth in the reference document of Nanobiotix filed with the French Financial Markets Authority (Autorité des Marchés Financiers) under number D.17-0470 on April 28, 2017 as well as in its 2017 annual financial report filed with the French Financial Markets Authority on March 29, 2018 (a copy of which is available on www.nanobiotix.com) and to the development of economic conditions, financial markets and the markets in which Nanobiotix operates. The forward-looking statements contained in this press release are also subject to risks not yet known to Nanobiotix or not currently considered material by Nanobiotix. The occurrence of all or part of such risks could cause actual results, financial conditions, performance or achievements of Nanobiotix to be materially different from such forward-looking statements. This press release and the information that it contains do not constitute an offer to sell or subscribe for, or a solicitation of an offer to purchase or subscribe for, Nanobiotix shares in any country. At the moment NBTXR3 does not bear a CE mark and is not permitted to be placed on the market or put into service until NBTXR3 has obtained a CE mark.

Attachment

Wildflower Brands Inc. (CSE: SUN) (OTCQB: WLDFF) ขึ้นเป็นจุดเด่นในสิ่งพิมพ์ของ NetworkNewsWire เกี่ยวกับอุตสาหกรรมสกัด CBD จากกัญชง

นิวยอร์ก, March 26, 2019 (GLOBE NEWSWIRE) — ผ่านทาง NetworkWire — NetworkNewsWire (“NNW”) บริษัทสำนักพิมพ์และสื่อข่าวการเงินในหลายแง่มุมวันนี้ประกาศการตีพิมพ์บทความที่มุ่งเน้นถึงบริษัท Wildflower Brands Inc. (CSE: SUN) (OTCQB: WLDFF)

เพื่ออ่านบทบรรณาธิการฉบับสมบูรณ์เกี่ยวกับการคาดการณ์อุตสาหกรรม CBD หลัง Farm Bill ผ่านไป กรุณาเข้าชมที่ http://nnw.fm/Q5q5a

กัญชงกำลังกลับมาอีกครั้งเนื่องจากความนิยมกัญชา (CBD) ที่กำลังสูงขึ้น CBD เป็นสารออกฤทธิ์ที่พบในกัญชาหลายรูปแบบ นี่คือส่วนประกอบที่บริษัทต่างๆเช่น Wildflower Brands Inc. (CSE: SUN) (OTCQB: WLDFF) ซึ่งเป็นผู้สร้างผลิตภัณฑ์เพื่อสุขภาพจากพืช ได้ใช้ประโยชน์อย่างกว้างขวางในช่วงไม่กี่ปีที่ผ่านมา

Farm Bill ได้รับแรงผลักดันส่วนมากจากความต้องการ CBD ที่เพิ่มขึ้น  เป็นสารเคมีที่ถูกปิดบังและไม่ค่อยได้พูดถึงในทศวรรษที่ผ่านมา CBD ได้กลายเป็นสินค้าอุปโภคบริโภคที่สำคัญ…  ได้รับการระบุว่าเป็นสารเคมีที่มีศักยภาพที่ดีต่อสุขภาพ CBD ถูกเริ่มนำมาทำการตลาดในสิทธิของตนเอง และถูกใช้ในผลิตภัณฑ์ต่างๆ เช่นสายผลิตภัณฑ์ Wildflower Wellness

กี่ยวกับ Wildflower Brands

Wildflower Brands เป็นบริษัทที่มีสำนักงานใหญ่ในเมืองแวนคูเวอร์ กำลังสร้างแบรนด์ต่างๆ ที่มีชื่อเสียงและผลิตภัณฑ์ที่มีคุณภาพ ซึ่งรวมเอาผลเสริมฤทธิ์จากพืชและสารสกัด เพื่อดูข้อมูลเพิ่มเติม กรุณาเยี่ยมชมเว็บไซต์ของบริษัทที่ www.WildflowerBrands.co

กี่ยวกับ NetworkNewsWire

NetworkNewsWire (NNW) เป็นบริษัทจัดจำหน่ายเนื้อหาและข่าวสารการเงิน ที่ให้บริการ (1) ให้เข้าถึงเครือข่ายบริการส่งข่าว NetworkWire เพื่อเข้าถึงตลาดเป้าหมายทั้งหมด อุตสาหกรรมต่างๆ และกลุ่มประชากรในลักษณะที่มีประสิทธิภาพมากที่สุด (2) บทความและการเผยแพร่บทบรรณาธิการถึงมากกว่า 5,000 ช่องข่าว (3) ปรับปรุงบริการข่าวประชาสัมพันธ์เพื่อให้เกิดผลกระทบสูงสุด (4) การเผยแพร่สื่อสังคมออนไลน์ผ่าน Investor Brand Network (IBN) ถึงผู้ติดตามเกือบ 2 ล้านคน (5) โซลูชั่นการสื่อสารองค์กรที่หลากหลายและ (6) บริการรายงานข่าวทั้งหมดด้วย NNW Prime   ในฐานะองค์กรที่มีหลายแง่มุม ด้วยทีมงานที่มีนักข่าวและนักเขียนจำนวนมาก NNW เป็นแห่งเดียวที่ให้บริการที่ดีที่สุดแก่บริษัทเอกชนและมหาชนที่ต้องการเข้าถึงกลุ่มนักลงทุน ผู้บริโภค นักข่าว และประชาชนทั่วไป   ด้วยการตัดผ่านข้อมูลที่มากเกินไปในตลาดทุกวันนี้ NNW ช่วยให้แบรนด์ของลูกค้าได้มองเห็นและรับรู้อย่างดี ด้วยวิธีที่ไม่มีใครเทียบเท่า NNW เป็นแหล่งรวมเนื้อหาข่าวสารและข้อมูล สำหรับข้อมูลเพิ่มเติมกรุณาเยี่ยมชม https://www.NetworkNewsWire.com

กรุณาดูข้อกำหนดการใช้งานและข้อความปฏิเสธความรับผิดชอบอย่างสมบูรณ์ในเว็บไซต์ NetworkNewsWire ซึ่งใช้บังคับกับเนื้อหาทั้งหมดที่จัดทำโดย NNW ไม่ว่าจะเผยแพร่แล้วหรือถูกเผยแพร่ซ้ำ ที่: http://NNW.fm/Disclaimer.

เพื่อรับ SMS แจ้งเตือนทันทีจาก NetworkNewsWire

พิมพ์ “STOCKS” และส่งถึง 77948

ข้อความคาดการณ์ล่วงหน้า

ข่าวประชาสัมพันธ์ฉบับนี้ประกอบด้วยแถลงการณ์ที่เป็นการคาดการณ์ล่วงหน้าตามความหมายของมาตรา 27A ของพระราชบัญญัติหลักทรัพย์ปี 1933 ที่ได้แก้ไขเพิ่มเติม และมาตรา 21E ของพระราชบัญญัติตลาดหลักทรัพย์ปี 1934 ที่ได้แก้ไขเพิ่มเติม   ข้อความคาดการณ์ล่วงหน้าทั้งหมดมีความไม่แน่นอน เนื่องจากขึ้นอยู่กับการคาดการณ์และสมมติฐานในปัจจุบันที่เกี่ยวข้องกับเหตุการณ์ในอนาคต หรือผลการดำเนินงานในอนาคตของบริษัท ผู้อ่านจึงไม่ควรเชื่อมั่นอย่างเกินควรต่อแถลงการณ์นี้ ซึ่งเป็นเพียงการคาดการณ์และพูดเฉพาะ ณ วันที่ที่ระบุไว้เท่านั้น  ในการประเมินแถลงการณ์ดังกล่าว นักลงทุนควรทบทวนความเสี่ยงและความไม่แน่นอนต่างๆที่ระบุไว้ในข่าวประชาสัมพันธ์ฉบับนี้อย่างรอบคอบ และข้อเท็จจริงต่างๆ ในเอกสารที่ยื่นต่อ SEC ของบริษัท  ความเสี่ยงและความไม่แน่นอนเหล่านี้อาจทำให้ผลลัพธ์ที่แท้จริงของบริษัทแตกต่างอย่างมากจากที่ระบุไว้ในแถลงการณ์คาดการณ์ล่วงหน้า

การสื่อสารองค์กร:

NetworkWire (NW)
นิวยอร์ก นิวยอร์ก
www.NetworkNewsWire.com
212.418.1217 สำนักงาน
Editor@NetworkWire.com

Multidisciplinary Experts Leverage Global Action for Local Impact to Protect Communities at Risk of Typhoid and Related Diseases

HANOI, Vietnam, March 25, 2019 (GLOBE NEWSWIRE) — Beginning today, the 11th International Conference on Typhoid and Other Invasive Salmonelloses brings together more than 450 researchers, policy makers and advocates who are dedicated to improving the lives of young children and their families suffering from typhoid, paratyphoid and invasive non-typhoidal Salmonella. During this three-day conference hosted by the Coalition against Typhoid, a program of the Sabin Vaccine Institute (Sabin), attendees from more than 40 countries will discuss the latest research and strategies to take on enteric fever, with the goal of translating recent global advancements into local impact for prevention and control at the community level.

Typhoid continues to cause an estimated 11 million cases and more than 116,000 deaths annually, largely affecting children in low-income communities in Asia and Sub-Saharan Africa. Prevention is more urgent than ever, with widespread antimicrobial resistance making the disease harder to treat. A recent outbreak of extensively drug-resistant typhoid in Pakistan exhibited resistance to five antibiotics, leaving only one oral antibiotic available for treatment.

Since the last conference in 2017, significant strides in global policy have paved the way for accelerated progress against enteric fever, beginning with the World Health Organization (WHO) prequalifying and subsequently recommending the use of typhoid conjugate vaccines. This is the first step toward protecting children as young as six months of age through routine immunization. Helping to ensure access to these vaccines for low-income countries, Gavi, the Vaccine Alliance (Gavi), committed $85 million in 2018 to support their introduction. Countries have begun to submit applications for Gavi support for routine immunization. Already, this life-saving intervention has been used for typhoid prevention and outbreak control in settings such as India, Pakistan and Zimbabwe.

“WHO and Gavi have taken the first step required for global typhoid prevention,” said Amy Finan, Sabin’s chief executive officer. “With our progress against typhoid being threatened by rising antimicrobial resistance, the time to take action at the country and community level is now. During the next three days, we will be laying the ground work for a coordinated prevention and control strategy to protect the millions of children who are most at risk of typhoid.”

“This year, we have a record-breaking number of researchers represented from all around the world,” said Dr. Denise Garrett, Sabin’s vice president of Typhoid Programs and director of the Coalition against Typhoid. “This clearly reflects the urgency we all feel to move forward on the path toward elimination of this ancient disease. I hope the discussions at this conference will channel the energy we have seen on the international stage to accelerate vaccination access and uptake at the local level.”

Organized with the generous support of Bharat Biotech, the Bill & Melinda Gates Foundation, IDL Biotech and the Typhoid Vaccine Acceleration Consortium (TyVAC), the 2019 conference is being held in Vietnam, a country that has demonstrated its commitment to controlling and preventing typhoid through intensive and targeted vaccination campaigns.

“I thank the organizers of the 11th International Conference on Typhoid and Other Invasive Salmonelloses for choosing Vietnam as the site for the crucial discussions that will help achieve global control of this disease,” said Dr. Dang Duc Anh, director of Vietnam’s National Institute of Hygiene and Epidemiology.

“This conference is a rare opportunity for researchers in the field of typhoid and related diseases to share their research and learn from each other,” said Dr. Anita Zaidi, director of the Vaccine Development, Surveillance, and Enteric and Diarrheal Diseases programs at the Bill & Melinda Gates Foundation. “Only by learning from one another and coordinating our efforts will we be able to control typhoid as a significant threat to health around the world.”

The agenda for the 11th International Conference on Typhoid and Other Invasive Salmonelloses is available to view on the Coalition against Typhoid website.

About the Sabin Vaccine Institute

The Sabin Vaccine Institute is a leading advocate for expanding vaccine access and uptake globally, advancing vaccine research and development, and amplifying vaccine knowledge and innovation. Unlocking the potential of vaccines through partnership, Sabin has built a robust ecosystem of funders, innovators, implementers, practitioners, policy makers and public stakeholders to advance its vision of a future free from preventable diseases. As a non-profit with more than two decades of experience, Sabin is committed to finding solutions that last and extending the full benefits of vaccines to all people, regardless of who they are or where they live. At Sabin, we believe in the power of vaccines to change the world. For more information, visit www.sabin.org and follow us on Twitter, @SabinVaccine.

Media Contact:
Anupama Varma
Senior Associate, Communications
Sabin Vaccine Institute
+1 (202) 621-1691
anupama.varma@sabin.org